Orphan medicinal products

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the designation and regulation of orphan medicinal products for rare diseases. Governed by the Human Medicines Regulations 2012 and the 2024 Windsor Framework amendments, the framework transitions to a UK-wide system on January 1, 2025. This allows products to receive orphan status in the UK regardless of their standing in the European Union. To qualify, medicines must treat life-threatening or chronically debilitating conditions with a UK prevalence of no more than 5 in 10,000, or demonstrate that development is otherwise financially unviable. Applicants must submit the official UK Orphan Drug Application Form alongside their Marketing Authorisation Application (MAA). The MHRA evaluates orphan criteria in parallel with the medicine's clinical assessment. Approved orphan products benefit from ten years of market exclusivity, preventing the authorization of similar products for the same indication. An additional two years may be granted for completed paediatric studies. Furthermore, the MHRA provides financial incentives, including fee waivers and refunds for small and medium-sized enterprises (SMEs). All authorized products are recorded in the public Orphan Register to manage exclusivity periods effectively.